Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

3 of 6
BACK NEXT
Abbott Laboratories
Abbott Laboratories

The drug and medical device maker recently received FDA approval for cholesterol drug Simcor, which could be a worthy contender for Vytorin, a drug created by rivals Merck and Schering-Plough.

And sales of Abbott's important Humira arthritis drug grew 42% over the fourth quarter, a good sign for the company. JPMorgan analyst Michael Weinstein thinks Abbott is worth buying. He expects earnings to grow 14% in 2008.

Abbott currently trades at about 17 times 2008 estimates and offers a dividend yield of 2.6%. And Abbott's dividend has increased 7% annually, on average, over the past five years. To put that in perspective, rivals such as Merck, Wyeth have boosted their payouts to investors by just 1% and 4% on average over the past few years.



NEXT: Federated Investors
Last updated June 20 2008: 1:23 PM ET
More Galleries
Here's what costs more than a barrel of oil Oil prices have crashed to below $27 a gallon -- a level not seen since 2003 -- which makes a barrel of crude cheaper than lots of everyday purchases that we don't think twice about. More
Super Bowl 50 ads are studded with celebrities The 2016 Super Bowl has rolled out the red carpet for the likes of Helen Mirren, Amy Schumer, Seth Rogen, Steven Tyler and the late, great Marilyn Monroe. More
The women of marijuana These women entrepreneurs and executives are making their mark in the marijuana industry. More

Special Offer